Certified Diabetes Educator Practice Exam 2025 - Free Practice Questions and Study Resource.

Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, primarily used to manage type 2 diabetes and provide cardiovascular benefits in certain populations. However, the use of Dapagliflozin is contraindicated in specific scenarios, particularly due to concerns about adverse effects and safety.

In the context of bladder cancer, Dapagliflozin should be avoided because there is a potential association between SGLT2 inhibitors and an increased risk of bladder cancer, especially in patients with a history of this condition. The data regarding this risk prompts caution in prescribing Dapagliflozin to those with a history of bladder cancer, leading to the conclusion that its use is not advisable in such cases.

While Dapagliflozin is associated with benefits in heart failure and has been studied for its applications in heart failure management, it is also noted that individuals with type 1 diabetes or those experiencing diabetic ketoacidosis should avoid using it due to the increased risk of acute complications and adverse outcomes. However, the most direct and significant contraindication among the choices provided relates specifically to its association with bladder cancer, making it the correct response in this context.